Effect of Dotinurad on Uric Acid and Hepatorenal Parameters in Steatotic Liver Disease: A Pilot Study in Japanese Patients

<b>Background:</b> Dotinurad (DOT) has demonstrated beneficial metabolic effects in preclinical models as a selective uric acid reabsorption inhibitor. However, its clinical impact on steatotic liver disease (SLD) with hyperuricemia (HU-SLD) remains unclear. <b>Methods:</b> This observational pilot...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Yuma Kamijo, Takanobu Iwadare, Takefumi Kimura, Kaede Fujita, Taiki Okumura, Shun-ichi Wakabayashi, Hiroyuki Kobayashi, Tomoo Yamazaki, Naoki Tanaka, Hideo Kunimoto
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	MDPI AG 2025-11-01
Seri Bilgileri:	Biomedicines
Konular:	alcohol-related liver disease dotinurad hyperuricemia metabolic dysfunction-associated steatotic liver disease selective urate transporter 1 modulator steatotic liver disease
Online Erişim:	https://www.mdpi.com/2227-9059/13/11/2716
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Effect of Dotinurad on Uric Acid and Hepatorenal Parameters in Steatotic Liver Disease: A Pilot Study in Japanese Patients

Benzer Materyaller